Pfizer Launches Vyndaqel For TTR-FAP Treatment In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer launched Vyndaqel (tafamidis meglumine) for the treatment of transthyretin familial amyloid polyneuropathy in Japan, the company announced on Nov. 20.